O
TARS icon

OrbiMed’s Tarsus Pharmaceuticals TARS Stock Holding History

OrbiMed’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.24M Buy
+35,581
New +$2.27M 0.04% 117
2026
Q1 		– Sell
-154,400
Closed -$12.6M – 129
2025
Q4 		$12.6M Sell
154,400
-43,500
-22% -$3.25M 0.26% 75
2025
Q3 		$11.8M Hold
197,900
– – 0.28% 69
2025
Q2 		$8.02M Sell
197,900
-455,843
-70% -$20.5M 0.2% 66
2025
Q1 		$33.6M Buy
+653,743
New +$32.3M 0.8% 34

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

OrbiMed's TARS Position: Q2 2026 in Review

OrbiMed opened a new position in Tarsus Pharmaceuticals (TARS) in Q2 2026: 35,581 shares worth $2.24M. The stake represents 0.04% of the portfolio and ranks #117 among its holdings. This is a return to the name: OrbiMed previously reported a position in TARS as recently as Q4 2025.

OrbiMed first reported a position in TARS in Q1 2025 and has held it in 5 quarters since. The position peaked at $33.6M in Q1 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • OrbiMed held 35,581 shares of Tarsus Pharmaceuticals worth $2.24M as of Q2 2026.
  • Tarsus Pharmaceuticals was a new OrbiMed position in Q2 2026.
  • Tarsus Pharmaceuticals made up 0.04% of OrbiMed's portfolio in Q2 2026, its #117 holding.
  • OrbiMed first reported a position in Tarsus Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • OrbiMed's Tarsus Pharmaceuticals position peaked at $33.6M in Q1 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.